Medigene to present at PIVAC Conference Rome
(Thomson Reuters ONE) -
Medigene AG /
Medigene to present at PIVAC Conference Rome
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Press Release
Martinsried/Munich, 25 September, 2014. Medigene AG (MDG1, Frankfurt, Prime
Standard) today presents at the 14(th) International Conference on Progress in
Vaccination Against Cancer taking place from 24 - 26 September in Rome. The
poster presentation entitled "Evaluation of a new generation dendritic cell-
based vaccine for treatment of patients with castration-resistant prostate
cancer" shows preclinical data on Medigene's immunotherapeutic DC vaccine
program. The abstract is available for download on Medigene's company website at
http://www.medigene.com/products-pipeline/development-
projects/immunotherapies/abstracts.
About Medigene's DC vaccines: The platform for the development of antigen-
tailored DC vaccines is the most advanced platform of the three highly
innovative and complementary immunotherapy platforms of Trianta Immunotherapies,
which was recently acquired by Medigene AG. Currently the DC vaccines are being
evaluated in two ongoing investigator-initiated trials in clinical phases II
(prostate cancer) and I/II (AML, acute myeloid leukaemia). Medigene concentrates
on the further development of DC vaccines in hematological malignancies and
plans to initiate a further clinical study in AML in 2014.
Medigene's dendritic cell product platform allows the design of new generation
dendritic cell vaccines. Dendritic cells can take up antigens efficiently,
process them and present them on their surface in a form that can induce T cells
to divide and mature. Dendritic cells can also induce natural killer cells to
become active and attack tumour cells. Medigene/Trianta has established new,
fast and efficient methods for preparation of autologous (patient-specific)
mature dendritic cells that have relevant characteristics to activate both T
cells and natural killer cells. They are developed to carry multiple tumour
antigens to treat various types of cancer, suited for treatment of minimal
residual disease or use in combination therapies.
About PIVAC: Progress in Vaccination Against Cancer (PIVAC) aims to bring
together translational and clinical oncologists and immunologists dealing with
active vaccination against cancer for three days of presentations on the most
recent advances in the field. Besides providing an up-to-date overview of many
aspects of tumour immunology, PIVAC fosters a lively and fruitful discussion,
promoting interactions between participants, speakers and companies attending
the conference and encouraging the emergence of new partnerships. More
information at: http://www.eacr.org/pivac14/index.php
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. Medigene concentrates
on the development of personalized T cell immunotherapies with a focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, which is distributed by commercial
partner companies. Medigene has advanced drug candidates which are licensed to
partners and additional candidates in clinical development. The company is
developing highly innovative treatment platforms concentrating on cancer and
autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) EndoTAG(®) and Veregen(® )are registered trademarks of Medigene AG.
These trademarks may be owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please visit:
http://www.medigene.de/unsubscribe
Press release as PDF:
http://hugin.info/132073/R/1858140/650741.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#1858140]
Unternehmensinformation / Kurzprofil:
Datum: 25.09.2014 - 08:00 Uhr
Sprache: Deutsch
News-ID 342805
Anzahl Zeichen: 5402
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 165 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene to present at PIVAC Conference Rome"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
